MedTrace Logo

Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer

NCT00795171 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-08-18

No results posted yet for this study

Summary

Docetaxel and sunitinib will be compared to docetaxel for their effect on CEC/CEP spikes induced by docetaxel in HRPC patients

Conditions

  • Hormone Refractory Prostate Cancer

Interventions

DRUG

Docetaxel * Sunitinib

docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles

DRUG

Docetaxel

docetaxel 75mg/m2 day1 q 21d x 4 cycles

DRUG

Docetaxel

Docetaxel 75mg/m2 q21d for 4 cycles

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Michael MK Krainer, MD · Dept of Internal Medicine I, Medical University Vienna, Austria

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-04-30
Completion
2011-07-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00795171 on ClinicalTrials.gov